U.S. Direct-to-Consumer Genetic Testing Market Size By Test (Carrier Testing, Predictive Testing, Ancestry & Relationship Testing, Nutrigenomics Testing, Skincare Testing), By Technology (Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, Whol

U.S. Direct-to-Consumer Genetic Testing Market Size By Test (Carrier Testing, Predictive Testing, Ancestry & Relationship Testing, Nutrigenomics Testing, Skincare Testing), By Technology (Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, Whole Genome Sequencing (WGS)), By Distribution Channel (Online Platforms, Over-the-Counter), Industry Analysis Report, Application Potential, Competitive Market Share & Forecast, 2023 - 2032

U.S. Direct-to-Consumer (DTC) Genetic Testing Market is expected to demonstrate substantial growth from 2023 to 2032. DTC genetic testing offers people access to genetic information without involving a healthcare provider or health insurance company. Besides, several benefits associated with DTC genetics, such as promoting awareness regarding genetic diseases, offering personalized health information, making people more proactive about their health, and being less expensive, are anticipated to further stimulate its demand in the coming years.

In addition, the U.S. DTC genetic testing market is anticipated to increase owing to the growing prevalence of rare genetic diseases. Moreover, technological innovations in the healthcare industry are also anticipated to foster the demand for DTC genetic testing. The constantly growing investments made in the healthcare infrastructure in the U.S. and the high accuracy & efficiency possessed by DTC genetic tests will surge the demand and prove beneficial for industry growth over the foreseeable period.

Conglomerates working in the U.S. direct-to-consumer (DTC) industry are persistently taking strategic initiatives to gain a competitive advantage in the overall market. To cite an instance, in January 2021, myDNA merged with Gene by Gene and FamilyTreeDNA. The two businesses have amalgamated to become one of the leading global experts in genealogy, pharmacogenomic and nutrigenomic services. Besides, the merger is grounded on several shared beliefs about the tremendous potential of genetic information.

Overall, the U.S. direct-to-consumer (DTC) genetic testing industry is segmented in terms of test type, technology, and distribution channel.

Based on test type, the carrier testing segment is anticipated to experience robust growth through 2032, primarily due to the increasing cases of rare genetic diseases. Carrier testing determines if an individual carries a genetic variation (allele) related to a specific disease or trait. The landscape of rare diseases is constantly changing as new rare conditions or diseases are regularly identified and reported, which is anticipated to help the segment grow in the coming years.

By technology, the targeted analysis segment was valued at over USD 542 million in 2022. The targeted analysis determines the defects in genes that cause disorders. Besides, targeted genotyping empowers researchers to focus more on specific regions of interest, generates a smaller and more manageable dataset, reduces data analysis burden, and offers a cost-efficient solution with decreased turnaround time compared to broader approaches.

On the basis of distribution channel, over-the-counter segment is anticipated to amass considerable gains during 2023-2032. DTC genetic testing devices and drugs available over the counter enable people to self-treat without the need for prescription, while saving health systems valuable resources and consumers’ money and time.